Holen Sie sich die Stockscreener-App
109.39
3.95%
4.16
Handel nachbörslich:
109.00
-0.39
-0.36%
Schlusskurs vom Vortag:
$105.23
Offen:
$105
24-Stunden-Volumen:
589.19K
Relative Volume:
0.94
Marktkapitalisierung:
$5.46B
Einnahmen:
$338.46M
Nettoeinkommen (Verlust:
$-310.96M
KGV:
-16.75
EPS:
-6.53
Netto-Cashflow:
$-132.82M
1W Leistung:
+5.94%
1M Leistung:
+0.38%
6M Leistung:
-16.93%
1J Leistung:
+28.92%
1-Tages-Spanne:
$104.15
$110.34
1-Wochen-Bereich:
$101.88
$110.34
52-Wochen-Spanne:
$75.56
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Firmenname
Axsome Therapeutics Inc
Sektor
Branche
Telefon
(212) 332-3241
Adresse
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Vergleichen Sie AXSM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
109.39 | 5.25B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-03 | Eingeleitet | Oppenheimer | Outperform |
| 2025-04-07 | Eingeleitet | Jefferies | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-31 | Bestätigt | Mizuho | Outperform |
| 2024-09-03 | Eingeleitet | Wells Fargo | Overweight |
| 2024-08-06 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-04-29 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-06 | Eingeleitet | UBS | Buy |
| 2024-01-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-08-08 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Eingeleitet | Piper Sandler | Neutral |
| 2022-11-01 | Eingeleitet | Loop Capital | Buy |
| 2022-09-07 | Fortgesetzt | Mizuho | Buy |
| 2021-08-10 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Eingeleitet | Berenberg | Buy |
| 2021-01-08 | Eingeleitet | Jefferies | Buy |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-09-29 | Eingeleitet | BofA Securities | Underperform |
| 2020-09-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-04-28 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-14 | Eingeleitet | Cowen | Outperform |
| 2019-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-17 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-16 | Bestätigt | Guggenheim | Buy |
| 2019-10-16 | Eingeleitet | Guggenheim | Buy |
| 2019-09-18 | Eingeleitet | William Blair | Outperform |
| 2019-05-28 | Eingeleitet | SunTrust | Buy |
| 2019-05-23 | Bestätigt | H.C. Wainwright | Buy |
| 2019-04-08 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-15 | Bestätigt | H.C. Wainwright | Buy |
| 2016-10-03 | Fortgesetzt | Brean Capital | Buy |
| 2015-12-15 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-12-14 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten
Virtu Financial LLC Acquires New Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Informed Momentum Co LLC Acquires New Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
XTX Topco Ltd Reduces Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
FY2026 EPS Estimates for AXSM Boosted by Cantor Fitzgerald - MarketBeat
HC Wainwright Issues Negative Estimate for AXSM Earnings - MarketBeat
HC Wainwright Issues Negative Outlook for AXSM Earnings - MarketBeat
Cantor Fitzgerald Issues Negative Forecast for AXSM Earnings - MarketBeat
Leerink Partnrs Issues Positive Forecast for AXSM Earnings - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Has $20.52 Million Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Equities Analysts Issue Forecasts for AXSM Q3 Earnings - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q2 2025 Earnings Call Transcript - MSN
Bank of America Issues Positive Forecast for Axsome Therapeutics (NASDAQ:AXSM) Stock Price - MarketBeat
TD Asset Management Inc Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics' (AXSM) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Royal Bank Of Canada Raises Axsome Therapeutics (NASDAQ:AXSM) Price Target to $189.00 - MarketBeat
Axsome outlines late-stage pipeline advancements and targets cash flow positivity amid 72% revenue growth - MSN
Axsome Therapeutics (NASDAQ:AXSM) Announces Quarterly Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
Federated Hermes Inc. Acquires Shares of 25,990 Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics Jumps 5% as Q2 Revenue Surpasses Projections - MSN
J. Safra Sarasin Holding AG Makes New $1.13 Million Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics’ Earnings Call Highlights Robust Growth - The Globe and Mail
Axsome Therapeutics: Strong Sales Performance and Promising Growth Trajectory Reinforce Buy Recommendation - TipRanks
Axsome Therapeutics: Strong Growth Prospects and Strategic Investments Justify Buy Rating - TipRanks
AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y - MSN
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings - 富途牛牛
Analysts Are Bullish on Top Healthcare Stocks: Mind Medicine (MNMD), Axsome Therapeutics (AXSM) - The Globe and Mail
Shareholders Have Faith in Loss-making Axsome Therapeutics (NASDAQ:AXSM) as Stock Climbs 6.1% in Past Week, Taking Three-year Gain to 146% - 富途牛牛
Axsome Therapeutics: BofA Securities Reiterates Buy Rating, Raises PT to $176. - AInvest
RBC Capital Reiterates Outperform on Axsome Therapeutics, Raises PT to $189 - AInvest
Axsome Therapeutics Reports Strong Q2 2025 Performance - The Globe and Mail
RBC Raises Price Target on Axsome Therapeutics to $189 From $184, Keeps Outperform Rating - MarketScreener
Axsome: Q2 Earnings Snapshot - New Haven Register
Axsome Therapeutics Inc (AXSM) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ... By GuruFocus - Investing.com Canada
Axsome Therapeutics Reports Strong Q2 2025 Growth - TipRanks
Axsome Therapeutics: Strong Sales Performance and Strategic Growth Initiatives Drive Buy Rating - TipRanks
Analysts bullish on AbbVie, Axsome Therapeutics, and GE Healthcare Technologies Inc. - AInvest
Axsome Therapeutics, Inc. SEC 10-Q Report - TradingView
Axsome Achieves 72% Revenue Growth, Sets Sights on Cash Flow Positivity - AInvest
Axsome Therapeutics, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:AXSM) - Seeking Alpha
Finanzdaten der Axsome Therapeutics Inc-Aktie (AXSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):